Drug Profile
Research programme: hepatitis C virus therapeutics - Ben-Gurion University/Sorrento Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ben Gurion University
- Developer Ben Gurion University; Sorrento Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Hepatitis-C in USA
- 09 Jul 2013 Early research in Hepatitis C in USA (unspecified route)